Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive TrialsMax Kates, Trinity J. Bivalacqua, Andrés Matoso et al.|Clinical Cancer Research|2019Cited by 167
Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial HistotypesJean Hoffman‐Censits, Andrés Matoso, Sonia Kamanda et al.|Applied immunohistochemistry & molecular morphology|2021Cited by 161
Molecular profile of bladder cancer progression to clinically aggressive subtypesCharles C. Guo, Bogdan Czerniak, Sangkyou Lee et al.|Nature Reviews Urology|2024Cited by 86
Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerRussell E.N. Becker, Trinity J. Bivalacqua, Alexa Meyer et al.|European Urology|2020Cited by 72
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER StudyNoah M. Hahn, Hristos Z. Kaimakliotis, Michael A. O’Donnell et al.|European Urology|2023Cited by 58